Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 63 for “"Disease-modifying therapy"”.
-
Disease modifying therapy for multiple system atrophy – Parkinsonian Type
… is a rare, rapidly progressive neurodegenerative disease without any current treatment. Recent research has increased the understanding of brain iron accumulation and its association with neurodegenerative synucleinopathies, like MSA-P. Because of this improved understanding of the disease …
-
Perceived Health Status, Adherence to Disease Modifying Therapy and Religious Coping in Adults with Multiple Sclerosis
Purpose: People living with MS need to employ both problem and emotion-focused coping strategies to maintain optimal health. Specifically, with one’s Perceived Health Status as an indicator of optimal health, treatment adherence and religious coping are indicators of problem and emotion-focused …
-
Delineating Avenues for a Novel Disease Modifying Therapy for Parkinson's Disease Using Advanced Fluorescence Microscopy Techniques
The most common mutation linked to Parkinson’s disease (PD) is the G2019S mutation of the leucine rich repeat kinase 2 (LRRK2) gene. LRRK2 is kinase active as a dimer and is involved in cellular maintenance through regulation of endocytosis and vesicle trafficking. The G2019S mutation has been …
-
Machine Learning Approaches and Web-Based System to the Application of Disease Modifying Therapy for Sickle Cell
Sickle cell disease (SCD) is a common serious genetic disease, which has a severe impact due to red blood cell (RBCs) abnormality. According to the World Health Organisation, 7 million newborn babies each year suffer either from the congenital anomaly or from an inherited disease, primarily from …
-
Determinants and Monitoring of Response to Disease-Modifying Therapy for Transthyretin Amyloidosis Cardiomyopathy: The ATTR-CM Therapy Study
… cardiomyopathy (ATTR-CM) is a heart muscle disease characterized by the accumulation of misfolded transthyretin proteins as amyloid plaques in the myocardial interstitium. In 2020, tafamidis, a medication inhibiting the misfolding of transthyretin, received Health Canada's approval for …
-
Applications of real time musculoskeletal ultrasonography in rheumatology practice
… structural damage has occurred, with early disease modifying therapy effective in improving long term outcomes. The first part of this thesis addresses the deficiency in our current knowledge of standardisation and reproducibility of ultrasound (US) findings. Chapter 2 describes a …
-
Vėlyvosios išsėtinės sklerozės klinikiniai, gydymo ir ligos eigos ypatumai /
… Aim. To determine the demographic, clinical, disease course, and treatment characteristics of people with late-onset multiple sclerosis compared with adult-onset multiple sclerosis. Objectives. To compare demographic characteristics and initial presentation. To compare diagnostic delay and the …
-
Evaluation of an α-Synuclein-Binding Aptamer for Reducing Pathological Protein Aggregation in a Cellular Model of Parkinson’s Disease Pathology
Parkinson’s disease (PD) pathology involves progressive accumulation of misfolded alpha synuclein (αSyn) aggregates, yet current treatments do not target this process. Aptamer-based therapeutics offer a novel strategy to disrupt αSyn aggregation. The single-stranded DNA aptamer a-syn-1 has …
-
Evaluation of fibrosis and anti-fibrotic therapeutics in systemic sclerosis
… (SSc) is a complex yet elusive connective tissue disease where vascular, immune, and fibrotic alterations occur. Nearly all organ systems are affected, leading to significant impacts on patients’ quality of life. A literature review was conducted to assess SSc pathogenesis and treatment options, …
-
Vitaminas D ir išsėtinė sklerozė. Klinikiniai atvejai /
… neurodegenerative central nervous system disease. The prevalence of disease has grown over the years and the numbers reach almost three million people worldwide. The first symptoms appear at around 20-40 years of age and three times more in women than in men. Multiple sclerosis is the …
-
Glutathione in Parkinson's disease
Parkinson’s Disease (PD) is one of several prevalent neurodegenerative diseases plaguing the aging population. To date, no therapies have been shown to slow, stop, or reverse disease progression; the disease is considered irreversible and progressive. Post mortem brain from individuals with …
-
Į naviką panaši išsėtinė sklerozė. Klinikiniai atvejai /
… to confirm the diagnosis. Corticosteroid pulse therapy is the first-line treatment of acute symptomatic tumefactive multiple sclerosis, and if the response is inadequate, plasmapheresis is administered. Disease-modifying therapy is usually initiated upon establishing the diagnosis of multiple …
-
Investigating the Safety and Therapeutic Potential of Vitamin D3 with Calcium Supplementation in Patients with Multiple Sclerosis
… relative to matched MS patients [age, sex, disease duration, disease modifying therapy, and expanded disability status scale (EDSS)] randomized to receive no supplementation. Mean serum 25(OH)D concentrations were 78.1±27.0 nmol/L at baseline and at one-year were 82.7±34.8 and 179.1±76.1 …
-
New Approaches against Alzheimer’s Disease Using Blood Brain Barrier Penetrating Nanotechnology
Alzheimer's Disease (AD) is a neurodegenerative disease affecting approximately 50 million people globally, with no cure or disease-modifying therapy available. However, new developments in nanotechnology offer hope for early detection and intervention in AD. Terpolymer was a novel biocompatible …
-
Fixel based analysis of relapsing remitting multiple sclerosis subjects
… fixel-based and DTI metrics for differing disease modifying therapy (DMT) treatments in the three brain regions. We found significant differences in both fixel-based and DTI metrics between RRMS subjects and healthy controls. We found that the NAWM adjacent to MS lesions showed significant …
-
Mapping networks of alpha-Synuclein proteostasis in cellular models of Parkinson's disease pathology
Parkinson’s disease (PD) is the second most common neurodegenerative disorder for which there is no disease-modifying therapy. Pathologically, the neuronal loss correlates with abnormal accumulation, aggregation and toxic gain of function of the small pre-synaptic protein alpha-Synuclein (aSyn). …
-
Study of Polyphenols and Naphthalimide Analogs As Inhibitors of Amyloid- β Protein Aggregation In Alzheimer'S Disease
Alzheimer's disease (AD) is a neurodegenerative disease and is the most common type of dementia. In the U.S., AD is the one of the leading causes of death and is the third most costly disease. Current therapies for AD mainly focus on symptomatic treatment, which delays the onset of AD by enhancing …
-
A combined cellular and bioinformatic approach to investigate RET-dependent and independent neurotrophic factors in models of Parkinson’s disease
Parkinson’s disease is a neurodegenerative disorder characterised by the progressive degeneration of midbrain dopaminergic neurons, driven by the pathological accumulation of α-synuclein protein in neurons throughout the nervous system. This neuronal loss underpins the characteristic motor …
-
INVESTIGATING MECHANISMS OF PEPTIDE INDUCED IMMUNE MODULATION OF MURINE MODELS OF ALLERGIC AIRWAYS DISEASE
… of Canadian asthmatics have poorly controlled disease. Thus, there remains pressing need to develop disease modifying therapies. Allergen-specific immunotherapy (SIT) is a disease-modifying therapy for allergic disease that consists of repeatedly administering doses of allergen, to an allergic …
-
Yeast as a Model for Studying Aβ Aggregation, Toxicity and Clearance
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of the central nervous system, characterised by acute memory loss and behavioural symptoms. The AD brain is characterized by the presence of senile amyloid plaques associated with degenerating neurites and inflammatory processes. …
Page 1 of 4